BR112020019824A2 - Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente - Google Patents
Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente Download PDFInfo
- Publication number
- BR112020019824A2 BR112020019824A2 BR112020019824-2A BR112020019824A BR112020019824A2 BR 112020019824 A2 BR112020019824 A2 BR 112020019824A2 BR 112020019824 A BR112020019824 A BR 112020019824A BR 112020019824 A2 BR112020019824 A2 BR 112020019824A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- chosen
- mmol
- alkyl
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650151P | 2018-03-29 | 2018-03-29 | |
| US62/650,151 | 2018-03-29 | ||
| PCT/US2019/024976 WO2019191667A1 (en) | 2018-03-29 | 2019-03-29 | Imidazopiperazine inhibitors of transcription activating proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020019824A2 true BR112020019824A2 (pt) | 2021-01-05 |
Family
ID=68057632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020019824-2A BR112020019824A2 (pt) | 2018-03-29 | 2019-03-29 | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11058688B2 (https=) |
| EP (1) | EP3773587A4 (https=) |
| JP (1) | JP7387627B2 (https=) |
| KR (1) | KR102815607B1 (https=) |
| CN (1) | CN112165944B (https=) |
| AU (2) | AU2019245403B2 (https=) |
| BR (1) | BR112020019824A2 (https=) |
| CA (1) | CA3095367A1 (https=) |
| IL (1) | IL277628A (https=) |
| RU (1) | RU2020131507A (https=) |
| WO (1) | WO2019191667A1 (https=) |
| ZA (1) | ZA202006092B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019245403B2 (en) | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| AU2021259814B2 (en) * | 2020-04-25 | 2023-09-28 | Pharmablock Sciences (Nanjing), Inc. | CBP/EP300 inhibitor and use thereof |
| JP7777131B2 (ja) * | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| WO2022072648A1 (en) * | 2020-10-02 | 2022-04-07 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| KR102910851B1 (ko) * | 2021-04-21 | 2026-01-09 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도 |
| CN113429427A (zh) * | 2021-07-05 | 2021-09-24 | 湖南南新制药股份有限公司 | 杂环化合物及其制备方法和药物用途 |
| CN115724857B (zh) * | 2021-08-25 | 2024-06-21 | 杭州禹泓医药科技有限公司 | 一种芳杂环类化合物、含其的药物组合物及其应用 |
| CN116410211A (zh) * | 2021-12-29 | 2023-07-11 | 山东新时代药业有限公司 | 一种苯并呋喃类化合物 |
| TW202340164A (zh) * | 2022-01-21 | 2023-10-16 | 大陸商深圳默元生物科技有限公司 | Ｎ－羥基喹啉甲醯胺化合物及其用途 |
| WO2023235809A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | Cgas inhibitors |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1537114B8 (en) | 2002-08-07 | 2007-10-03 | Novartis AG | Organic compounds as agents for the treatment of aldosterone mediated conditions |
| AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| MX2008015008A (es) | 2006-05-26 | 2008-12-05 | Novartis Ag | INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA. |
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| ATE545647T1 (de) | 2006-12-22 | 2012-03-15 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazoä1,5-aüpyrazinderivat |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| EP2170350B1 (en) | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| KR20110036069A (ko) | 2008-06-25 | 2011-04-06 | 액테리온 파마슈티칼 리미티드 | 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물 |
| EA021293B1 (ru) * | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP2528918B1 (en) | 2010-01-29 | 2014-09-10 | Nerviano Medical Sciences S.r.l. | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| CN103087067A (zh) * | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途 |
| EP2920173B1 (en) | 2012-10-18 | 2016-11-23 | Bristol-Myers Squibb Company | Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists |
| WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| JP2016525503A (ja) * | 2013-06-28 | 2016-08-25 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| WO2016055028A1 (en) | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| US9763922B2 (en) * | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| MA45122A (fr) | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| EP3464286B1 (en) * | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| AU2019245403B2 (en) | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
-
2019
- 2019-03-29 AU AU2019245403A patent/AU2019245403B2/en active Active
- 2019-03-29 CA CA3095367A patent/CA3095367A1/en active Pending
- 2019-03-29 EP EP19777484.7A patent/EP3773587A4/en active Pending
- 2019-03-29 BR BR112020019824-2A patent/BR112020019824A2/pt not_active Application Discontinuation
- 2019-03-29 WO PCT/US2019/024976 patent/WO2019191667A1/en not_active Ceased
- 2019-03-29 JP JP2020551963A patent/JP7387627B2/ja active Active
- 2019-03-29 CN CN201980035368.2A patent/CN112165944B/zh active Active
- 2019-03-29 US US16/370,404 patent/US11058688B2/en active Active
- 2019-03-29 RU RU2020131507A patent/RU2020131507A/ru unknown
- 2019-03-29 KR KR1020207031004A patent/KR102815607B1/ko active Active
-
2020
- 2020-09-27 IL IL277628A patent/IL277628A/en unknown
- 2020-10-01 ZA ZA2020/06092A patent/ZA202006092B/en unknown
-
2021
- 2021-05-21 US US17/327,217 patent/US12186324B2/en active Active
-
2024
- 2024-11-06 US US18/938,730 patent/US20250127792A1/en active Pending
-
2025
- 2025-04-29 AU AU2025202971A patent/AU2025202971A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3773587A4 (en) | 2021-09-29 |
| KR20210003764A (ko) | 2021-01-12 |
| JP7387627B2 (ja) | 2023-11-28 |
| US20190298729A1 (en) | 2019-10-03 |
| CN112165944A (zh) | 2021-01-01 |
| US20230008047A1 (en) | 2023-01-12 |
| RU2020131507A (ru) | 2022-05-04 |
| CN112165944B (zh) | 2024-04-09 |
| AU2019245403A1 (en) | 2020-10-22 |
| ZA202006092B (en) | 2022-11-30 |
| US20250127792A1 (en) | 2025-04-24 |
| US11058688B2 (en) | 2021-07-13 |
| CA3095367A1 (en) | 2019-10-03 |
| AU2025202971A1 (en) | 2025-05-15 |
| US12186324B2 (en) | 2025-01-07 |
| JP2021519308A (ja) | 2021-08-10 |
| IL277628A (en) | 2020-11-30 |
| AU2019245403B2 (en) | 2025-02-06 |
| KR102815607B1 (ko) | 2025-05-30 |
| EP3773587A1 (en) | 2021-02-17 |
| WO2019191667A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12186324B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| ES2895257T3 (es) | Inhibidores de biciclo[1.1.1]pentano de cremallera de leucina doble cinasa (DLK) para el tratamiento de una enfermedad | |
| ES2788449T3 (es) | Inhibidores de GLS1 para tratar enfermedades | |
| US10899769B2 (en) | Imidazopiperazinone inhibitors of transcription activating proteins | |
| ES2794868T3 (es) | Inhibidores de GLS1 para el tratamiento de enfermedades | |
| JP2017503815A (ja) | がんまたは炎症性疾患を処置するための置換されたピロロピリジンおよびピロロピラジン | |
| US12559497B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| AU2020391425A1 (en) | Inhibitors of Receptor Interacting Protein Kinase 1 for the treatment of disease | |
| US12540139B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| BR112017028309B1 (pt) | Composto e composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |